StockNews.com Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold

StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a sell rating to a hold rating in a research report sent to investors on Thursday.

Several other analysts have also issued reports on AGIO. JPMorgan Chase & Co. restated a neutral rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. Royal Bank of Canada upped their price target on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the company an outperform rating in a research report on Tuesday, June 4th. The Goldman Sachs Group upped their price target on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a neutral rating in a research report on Tuesday, June 4th. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of Hold and a consensus target price of $50.67.

Agios Pharmaceuticals Stock Up 3.4 %

AGIO opened at $45.88 on Thursday. The stock has a market cap of $2.60 billion, a PE ratio of -7.26 and a beta of 0.79. Agios Pharmaceuticals has a 52 week low of $19.80 and a 52 week high of $49.06. The business’s fifty day simple moving average is $40.35 and its 200 day simple moving average is $32.09.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.20. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The business had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $8.37 million. During the same quarter in the prior year, the firm earned ($1.47) earnings per share. The firm’s revenue was up 46.0% on a year-over-year basis. As a group, equities analysts anticipate that Agios Pharmaceuticals will post -2.68 earnings per share for the current year.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors have recently modified their holdings of AGIO. Harbor Capital Advisors Inc. raised its stake in Agios Pharmaceuticals by 70.0% in the second quarter. Harbor Capital Advisors Inc. now owns 32,770 shares of the biopharmaceutical company’s stock worth $1,413,000 after buying an additional 13,494 shares in the last quarter. Farallon Capital Management LLC raised its stake in Agios Pharmaceuticals by 34.1% in the first quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock worth $163,469,000 after buying an additional 1,423,000 shares in the last quarter. Tidal Investments LLC bought a new position in Agios Pharmaceuticals in the first quarter worth about $946,000. Kennedy Capital Management LLC bought a new position in Agios Pharmaceuticals in the first quarter worth about $4,658,000. Finally, Caxton Associates LP bought a new position in Agios Pharmaceuticals in the first quarter worth about $1,087,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.